Piramal Pharma Limited (PPL) reports that Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India. PPL holds a strategic minority stake in Yapan and markets its services through Piramal Pharma Solutions (PPS), a CDMO serving the global pharmaceutical and biotech market.
With this expansion, Yapan Bio has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids, according to PPL officials. The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.
The new labs will allow Yapan Bio to optimize the utilization of the GMP facility to support manufacturing of clinical trial material for the clients, noted Nandini Piramal, chairperson, PPL.
“This new facility, which is part of our $8 million expansion plan for Yapan Bio, represents the first major step in the Piramal/Yapan partnership since our initial investment back in December 2021,” said Piramal. “It’s evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients. With this investment, the Yapan team can conduct a larger number of projects than before, resulting in the development and delivery of more novel products for clinical evaluation and ultimately, better, and faster treatments for patients.”
